• Patients who provide written informed consent form (ICF) to participate in the study.

• Male and female.

• ≥ 18 years old.

• Diagnosis of moderate or severe HS (Hurley stage and IHS4).

• Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF.

• Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation.